Opioid Promos Left Out Risks, FDA Says in Warning Letter

Drug Industry Daily
A A
The FDA directed a Canadian opioid manufacturer to send information to doctors correcting the complete absence of warnings of serious risks associated with the drug in professional promotional materials distributed earlier.

To View This Article:

Login

Subscribe To Drug Industry Daily